Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) announced topline results from Phase 1b Callisto trial designed to evaluate TP-05, a novel investigative oral therapeutic for the potential prevention of Lyme disease.
Results from the trial showed that TP-05 was well tolerated with no dose-related or drug-related serious adverse events.
Pharmacokinetic data from the trial demonstrated rapid absorption and an extended half-life of TP-05, potentially supporting a monthly or less frequent therapy regimen.
Additionally, exploratory ex-vivo tick kill modeling utilizing serum from TP-05-treated subjects demonstrated potent, rapid killing of adult and nymph ticks.
Tarsus also announced the enrollment of the first patient in the Carpo Phase 2a trial, evaluating TP-05 for potentially preventing Lyme disease in humans.
TP-05 is an oral systemic formulation of lotilaner, a well-characterized anti-parasitic agent that selectively inhibits parasite-specific GABA-CI channels.
Lyme disease is transmitted through Borrelia burgdorferi infection following the bite of a tick vector. Over 30 million Americans are at high or moderate risk of contracting Lyme disease, and there are approximately 300,000 – 400,000 cases in the U.S. each year.
Price Action: TARS shares are down 1.60% at $14.75 on the last check Thursday.
Photo Via Company
See more from Benzinga
Parkinson's Study Using CRISPR Technology Shows Promise, Seelos Therapeutics Says
Synlogic's Experimental Drug Lowers Urinary Oxalate In Gastric Bypass Patients
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
